Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida

All Publications

11-2019

Incidental MITF, p.E318K Pathogenic Variant in Three Independent Cases Undergoing Hereditary Cancer Risk Assessment

Jessica Ordonez Miami Cancer Institute, jessicaord@baptisthealth.net

Jeffrey Boyd Miami Cancer Institute, JeffreyB@baptisthealth.net

Arelis Martir-Negron Baptist Health Medical Group; Miami Cancer Institute, arelisma@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation

Ordonez, Jessica; Boyd, Jeffrey; and Martir-Negron, Arelis, "Incidental MITF, p.E318K Pathogenic Variant in Three Independent Cases Undergoing Hereditary Cancer Risk Assessment" (2019). *All Publications*. 3387. https://scholarlycommons.baptisthealth.net/se-all-publications/3387

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

Incidental MITF, p.E318K Pathogenic Variant in Three Independent **Cases Undergoing Hereditary Cancer Risk Assessment**


Background

- The *MITF*, p.E318K mutation has been described as a rare risk factor for melanoma and renal cell carcinoma².
- Associated risks for the *MITF*, p.E318K mutation have been mostly ascertained by studying melanoma cohorts ¹⁻³.
- Little is known about the incidence of *MITF*, p.E318K or the \bullet natural history of *MITF*, p.E318K carriers in non-melanoma cohorts.
- We describe three cases where the *MITF*, p.E318K mutation was incidentally identified during hereditary cancer risk assessment.

				-
	Clinical History	Cases		
	Clinical History	Case 1	Case 2	Case 3
-	Age	49	43	52
	Gender (M/F)	Female	Female	Female
	Ethnicity/ Race	Hispanic White	Hispanic White	Hispanic W
	<section-header><text></text></section-header>	None	None	Yes • CRC • Adenocarcinoma at descending colon • Normal immunohistochemistr for Mismatch Repair (MMR) genes
	Reason for referral	Family history of breast, ovarian and pancreatic cancer	Family history of fallopian tube cancer and pancreatic cancer	Newly diagnosed colo history of colon, endom cancer.
	Met HBOC genetic testing NCCN guidelines at assessment?	Yes	Yes	No
	Met Lynch Syndrome genetic testing NCCN guidelines at assessment?	No	No	Yes
	Genetic testing pursued	81-gene panel	75-gene panel	67-gene pa
	Assay	CustomNext- Cancer ®	CustomNext -Cancer ®	CancerNext-Ex

Clinical History

Jessica Ordonez, MS, CGC,¹ Cristina Flanagan, MMSc, CGC,^{1,2} Jeff Boyd, PhD, ¹ & Arelis Martir-Negron, MD, FACMG, ¹ ¹ Miami Cancer Institute, Center for Genomic Medicine, Baptist Health South Florida; ² Myriad Genetics Laboratory



Case 3 *MITF,* c.952G>A; **p.E318K**

RAD51C, c.719T>C

BRCA2, c.9925GA

MITF Risks & Proposed Recommendations *					
	Lifetime Risks	Screening	Age to begin		
Malanama	~5-20%	Annual full body dermatologic	~20 y		
Melanoma	(vs. ~2.5% USA population risk)	exam	(Median age of onset 31-71 y ³)		
		Baseline urology evaluation			
Renal Cell Carcinoma (RCC)	~8% (vs. 1.6% USA population risk)	Consideration of annual renal	~25-30 y		
		imaging with renal ultrasound. Consider alternating with MRI.	(Median age of onset 35-72 y ⁴)		
		Consideration of annual urinalysis			

melanoma and RCC

- identified.

- Limitations:

1. Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d'Hayer, B., Mohamdi, H., Remenieras, A., Maubec, E., de la Fouchardiere, A., and 45 others. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480: 94-98, 2011.

- Pigment Cell Melanoma Res, 26: 259-262.
- Eur Urol (2019).







* Based on available literature, geographic location, and screening guidelines for other genetic syndromes associated with

Discussion

As multigene panel testing continues to gain popularity in clinical practice, incidental pathogenic variants are also more commonly

The challenge of incidental findings is heightened in genes with limited data on lifetime risks and incomplete penetrance.

We highlight the importance of the development of clinical guidelines for newly described hereditary cancer genes to standardize recommendations, better understand risks for carriers in other populations, and justify medical necessity for management changes based on incidental genetic test results.

Small sample size. Limited data on longitudinal follow-up to assess the clinical impact of incidental findings.

References

2. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature. 2011; 480 (7375): 94-98.

3. Ghiorzo, P., Pastorino, L., Queirolo, P., Bruno, W., Tibiletti, M.G., Nasti, S., Andreotti, M., Paillarets, B.B. and Bianchi Scarra, G. (2013), Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.

4. Carlo MI, et al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Acknowledgements

We would like to thank our patients for their engagement in genetic risk assessment. We would also like to thank our entire team at the Division of Clinical Genetics for their tireless support!